Rapid, convenient radioimmunoassay of estrone sulfate

¹ Diagnostic Systems Laboratories, 445 Medical Center Blvd., Webster, TX 77598-4217.

² Diagnostic Systems Laboratories, 600 University Ave., Room 653, Toronto, Ontario M5G1X5, Canada.

³ Texas Tech University, Health Science Center, Department of Obstetrics and Gynecology, 1400 Wallace Rd., Amarillo, TX 79106-1797.

⁴ University of Southern California School of Medicine, Women and Children's Hospital, 1240 N. Mission Rd., Los Angeles, CA 90033.
^a Author for correspondence. Fax (281) 554-4220.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
We developed a specific, simple, and rapid RIA for the direct quantification of estrone sulfate (E₁S) and established its performance characteristics. The assay has a dynamic range of 0.05–90 µg/L with a detection limit of 0.009 µg/L. Intraassay CVs were 9.2%, 4.5%, and 4.6% at 0.35, 9.0, and 60 µg/L, respectively. Interassay CVs were 8.8%, 5.1%, and 5.5% at 0.076, 0.5, and 12 µg/L, respectively. Linearity of dilution studies showed values of 80–105% of expected, and recovery of E₁S added to serum samples ranged from 82% to 102%. Cross-reactivities with structurally related estrogens were <5%. When compared with a conventional assay (involving hydrolysis of E₁S and indirect measurement of estrone), the present RIA showed excellent correlation (r = 0.99, slope = 1.54, S_yx = 2.14, n = 71). Mean E₁S concentrations measured with this RIA for normal men (n = 20) and women in follicular (n = 20) and luteal (n = 25) phases of their menstrual cycle were 0.96, 0.96, and 1.74 µg/L, respectively. Mean E₁S concentrations for oral contraceptive users (n = 20) and postmenopausal women without hormone replacement therapy (n = 21) or on hormone replacement therapy (n = 22) were 0.74, 0.13, and 2.56 µg/L, respectively. Serum concentrations of E₁S in pregnant women in their first (n = 14), second (n = 17), and third (n = 15) trimesters were 20, 66, and 105 µg/L, respectively. Availability of this simple RIA should provide a useful tool for the assessment of estrogen status in women.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Estrone sulfate (E₁S)¹ is quantitatively the most important circulating estrogen in a woman (1)(2). Formation of E₁S occurs in a variety of tissues in the body but primarily in the liver. A number of tissues in the body contain sulfatases that can transform the biologically inactive E₁S, by hydrolysis, to estrone (E₁). The latter estrogen can then be converted to the potent estrogen, estradiol (E₂), through action of the enzyme, 17ß-hydroxysteroid dehydrogenase. Thus, it appears that the body keeps a reserve of estrogen in an inactive form, and when more of the active estrogen is needed, it becomes readily available.

Conventionally, E₁ and E₂ have been used as the markers of estrogenicity, in spite of their limitations, such as low serum concentrations and diurnal variations, which can be misleading for clinicians in patient management, depending on the time of collection of serum samples. E₁S has a clear advantage over the existing markers because: (a) serum concentrations of E₁S are 10–20-fold higher than E₁ or E₂; therefore, reliable determination of E₁S concentrations is possible and would minimize the interassay variation; (b) E₁S has a slow metabolic clearance rate, which would maintain the constant serum concentration with no diurnal variation; (c) E₁S does not bind to sex hormone-binding globulin, whereas E₂ does; as a result, the measurement of E₂ with most commercially available immunoassays reflects large interlaboratory variability because of differences in affinities and specificities of antibodies toward the sex hormone-binding globulin-bound form and the free form of E₂.

Until now, the limited utility of E₁S as an estrogenicity marker could be attributed to the lack of availability of a simple and highly specific assay for E₁S. The conventional assays for the measurement of E₁S are either cumbersome and time consuming, involving hydrolysis of E₁S to E₁ followed by the extraction and indirect determination of E₁S via measurement of E₁ (3), or lack antibody specificity. For example, two earlier reports described the measurement of E₁S by using antibodies that were not raised specifically against E₁S but against its nonsulfated derivatives such as estrone glucuronide and estrone 3-methyl phosphorthionate (4)(5)(6). Both reports describe the use of H-labeled E₁S, which has the obvious limitation of lower sensitivity. Another report used a detection system based on reactions of free radicals; its dynamic range was narrow: 5–1000 ng/L (7).

In this report, we: (a) describe the development and performance characteristics of a simple, rapid, and highly specific RIA for the direct measurement of E₁S in serum or plasma; (b) compare the new assay with an established conventional method requiring hydrolysis, extraction, and indirect determination of E₁S through measurement of E₁; and (c) establish reference ranges for men and women to expand the clinical utility of this assay.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
subjects
Male volunteers were apparently healthy and not on any medication. Normally cycling women in this study were arbitrarily divided into luteal and follicular phase on the basis of cycle length and endocrine status and did not exhibit any symptoms of hyperandrogenism. A group of women on oral contraceptives was also investigated. Postmenopausal women were those who had not had a regular menstrual cycle for at least 9 to 12 months and who were in their late 40s to early 50s. Cross-sectional samples were obtained from normal singleton pregnant women at the first, second, and third trimesters.

materials
E₁S and bovine serum albumin (BSA) were obtained from Sigma Chemical Co. All other chemicals were purchased from Aldrich Chemical Co. unless stated otherwise.

Radioactivity was measured in the Packard Multichannel RIA System Counter (Model B 5424).

preparation of assay components
Synthesis of estrone-3-sulfate-6-(O-carboxymethyl)-oxime (CMO).
Estrone 6-CMO (20 mg, 0.056 mmol) and sulfur trioxide–triethylamine complex (30 mg, 0.215 mmol) in dry pyridine (0.3 mL) were stirred at room temperature for 16 h. The solvent was removed under vacuum. The crude product was purified by preparative thin-layer chromatography on silica gel (Analtech; 250-µm particles) by using chloroform:methanol:ammonium hydroxide (15:5:1 by vol) as a solvent system. The yield of diammonium salt of estrone-3-sulfate-6-CMO was 26.5 mg.

Synthesis of estrone-3-sulfate-6-CMO:BSA conjugate.
Estrone-3-sulfate-6-CMO diammonium salt (43.2 mg, 0.0916 µmol) in dimethylformamide (3.0 mL) was added to 1,4-dioxane (2.0 mL). The mixture was cooled to 4 °C, followed by the addition of tri-n-butylamine (23.2 µL). The mixture was stirred for 10 min, followed by the addition of isobutyl chloroformate (17.4 µL). The resulting solution was added dropwise to the solution containing water (6 mL), dioxane (2 mL), and BSA (98.5 mg, 1.53 µmol) at 2–4 °C. The pH was maintained between 8.0 and 8.5 during the addition. The turbid reaction mixture was stirred at 4 °C for 20 h. The mixture was dialyzed against 50 mmol/L sodium bicarbonate (pH 8.5) with two changes, followed by dialysis against water. The dialysate was lyophilized to give E₁S-6-CMO:BSA conjugate (65 mg). Fig. 1 illustrates the synthesis of this immunogen.

View larger version (15K): [in this window] [in a new window]   Figure 1. Synthesis of estrone-3-sulfate:BSA and estrone sulfate-6-CMO-histamine.

Synthesis of estrone-3-sulfate-6-CMO-histamine.
Estrone-3-sulfate-6-CMO (5.6 mg), diisopropylethylamine (4 µL), histamine (2 mg, 0.018 µmol), and diethylphosphoryl cyanide (5 µL) in dry dimethylformamide (160 µL) were stirred at room temperature for 24 h under argon. The solvent was removed under vacuum, and the residue was purified on preparative thin-layer chromatography by using chloroform:methanol:ammonium hydroxide (15:5:1 by vol) as a solvent system. Estrone-3-sulfate-6-CMO-histamine was obtained as an amorphous white solid (4.3 mg; Fig. 1 ) as a precursor for I-labeled tracer.

I-labeled estrone sulfate tracer.
Estrone-3-sulfate-6-CMO-histamine was iodinated with NaI by using Chloramine-T (8) in phosphate-buffered saline. The radioactive compound was then purified by reversed-phase chromatography on an octadecylsilyl column by using methanol:water containing triethylamine, 1 mL/L, as an elution system. The purified compound (~1.4 mCi/µg) was stored undiluted at -20 °C.

Generation of antiserum.
Two rabbits were immunized with estrone-3-sulfate:BSA conjugate by following the protocol described previously (9). Briefly, the primary injection (2 mg) of the conjugate in isotonic saline was mixed with an equal volume of Freund's complete adjuvant at a final dilution of 1 g/L. It was divided in four equal portions and injected intramuscularly into each thigh and below each shoulder blade. Three booster shots were given (0.5 mg) on days 7, 14, 21, and every 30 days thereafter (50 µg/rabbit). Serum was collected 14 days after the third booster and every 30 days thereafter. These antisera were tested for their ability to bind to E₁S tracer. Antiserum from one rabbit displayed high titer and was able to displace the iodinated antigen tracer with increasing concentrations of unlabeled analyte.

ria for direct measurement of estrone sulfate in serum or plasma
Calibrators, controls, or unknown patient samples (100 µL) were added to the polypropylene tubes, followed by E₁S I-labeled tracer (100 µL) and E₁S antiserum (100 µL). The tubes were incubated at room temperature on a shaker for 3 h, followed by the addition of the precipitating reagent, goat anti-rabbit IgG (1 mL). The samples were allowed to stand for 10 min, followed by centrifugation for 15 min at 1500g. The supernate was then decanted, and its radioactivity was counted for 1 minute.

indirect measurement of e₁s by a conventional method
Samples were hydrolyzed, and the released E₁ was measured as described elsewhere (4). Briefly, 0.2 mL of serum/plasma samples supplemented with 500 cpm of tritiated E₁S (New England Nuclear; specific activity, 40–60 Ci/mmol) in 0.1 mL of assay buffer were incubated at 37 °C for 30 min, followed by extraction with 10 mL of ethyl acetate:hexane (4:6 by vol) to remove unconjugated steroids. The aqueous phase was then deproteinized by the addition of 2 mL of methanol. The protein pellet was removed by centrifugation, and the methanol layer was evaporated under nitrogen. The residue was reconstituted with 2.0 mL of 0.1 mol/L sodium acetate buffer (pH 5.0), and E₁S was hydrolyzed with arylsulfatase (type VII from abalone entrails, Sigma Chemical Co.) at 37 °C for 16–18 h. The hydrolyzed estrogens were extracted twice with 5 mL of ethyl acetate:hexane (4:6 by vol). The solvent was evaporated, and the residue was redissolved in 1 mL of assay buffer:ethanol (9:1 by vol) and used for the indirect estimation of E₁S by using a RIA for E₁.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Figure 1 illustrates the synthesis of E₁S-6-CMO-BSA as the immunogen and E₁S-6-CMO-histamine as the precursor molecule to I-labeled tracer, both of which were synthesized from E₁S-6-CMO, which in turn was obtained via chemical sulfation of E₁-6-CMO.

For the development of direct RIA for E₁S, various antiserum titers, sample and tracer volumes, incubation times, and temperatures were investigated. Ideal conditions in terms of assay performance are described in Materials and Methods. With these conditions, the calibration curve was useful over the range of 0.05 to 90.0 µg/L with 50% displacement at 2.5 µg/L. A linear/log transform of a typical calibration curve is shown in Fig. 2 .

View larger version (10K): [in this window] [in a new window]   Figure 2. Calibration curve for estrone sulfate.

performance characteristics
Sensitivity.
The limit of detection, as determined by interpolating the mean - 2 SD of 12 replicates of the zero standard, was 0.009 µg/L.

Precision.
The intraassay and interassay CVs are shown in Table 1 . The intraassay variation was calculated from the 16 replicates each of the three serum samples containing various endogenous concentrations of E₁S. The CVs were <10% for each sample. The interassay variation was calculated from multiple analyses (n = 8) of three different serum samples. The CVs were <10% for all samples.

Analytical recovery.
Recovery experiments were carried out with serum samples containing low endogenous concentrations of E₁S to which three different amounts of exogenous E₁S had been added. The samples were then analyzed (Table 2 ). In each case, the amount recovered was >80%.

Linearity of dilution.
Three serum samples with low, medium, and high endogenous concentrations of E₁S were diluted serially with the zero calibrator. It showed the values between 80% and 105% of expected, and the regression analysis showed E₁S (expected) = 0.93 E₁S (observed) - 0.0074, r = 0.99, indicating that the assay procedure maintains good linearity of dilution.

Specificity.
The cross-reactivity of the antiserum used for the development of RIA of E₁S is shown in Table 3 . The antiserum shows relatively low cross-reactivity to the unconjugated estrogens and nonestrogenic steroids. E₁ and estrone 3-glucuronide showed <5% cross-reactivity.

comparison of direct ria with conventional method for the measurement of e₁s
E₁S values were measured in 71 serum samples by the new, direct RIA (y) and by an established, conventional method (x) that utilized hydrolysis, extraction, and subsequent E₁ measurement by RIA (thus, indirectly calculating E₁S values). Regression analysis (Fig. 3 ) of the samples yielded the equation:

View larger version (14K): [in this window] [in a new window]   Figure 3. Comparison of serum values of E1S obtained by new RIA and by indirect measurement of E1S after solvolysis.

substantial equivalence between e₁ and e₁s
Forty-one samples were evaluated for E₁S and E₁ (DSL 8700, estrone RIA kit). The correlation coefficient was 0.86, with P <0.0001 showing substantial equivalence of the two steroids in the same patient sample (Fig. 4 ).

View larger version (14K): [in this window] [in a new window]   Figure 4. Comparison of serum values of E1S and E1 (DSL 8700).

comparison of serum vs plasma e₁s
Analysis of serum and plasma obtained from the same subjects (n = 32) for E₁S in the new RIA showed no significant difference in E₁S values, indicating that the assay can be used to measure E₁S concentrations in serum or plasma (r = 1.0).

e₁s in men and women
The new RIA was used to measure E₁S values in serum samples from normal, apparently healthy men, premenopausal women in their different phases of menstrual cycle or on oral contraceptive regimen, women in their first, second, or third trimester of pregnancy, and postmenopausal women with or without hormone replacement therapy (HRT; Premarin). Fig. 5 shows the E₁S concentrations in various groups of subjects.

View larger version (12K): [in this window] [in a new window]   Figure 5. E1S concentrations (mean ± SE). (a) Different groups of samples; (b) during pregnancy. The numbers of subjects (a) or numbers of subjects at each trimester (b) are indicated in parentheses.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
E₁S is quantitatively the most important circulating estrogen in a woman. Its production rate fluctuates during the menstrual cycle, similar to that observed for E₂ and E₁. Estrogen status in women is conventionally determined primarily on the basis of serum concentrations of E₂ and sometimes serum E₁. There has been considerable interest in the third serum marker, E₁S, which is biologically inactive and can be readily converted into E₁ and E₂. Because the circulating pool of E₁S can be conceptualized as a slowly metabolized estrogen reservoir, it has gained marked importance in assessing estrogenicity in a woman. However, few studies have been done on the potential diagnostic utility of E₁S (5), primarily because its measurement has required cumbersome conventional methodology involving many steps of extraction, hydrolysis, and reextraction before its measurement by RIA. This poses practical limitations on the measurement of E₁S. Moreover, some antibodies used to determine E₁S lack specificity because they were raised against estrone glucuronide and possessed high cross-reactivity to E₁S.

In the present study, the antiserum against E₁S was prepared by linking the carrier protein through the 6-position in ring B of the steroid skeleton. This presumably retained the stereochemistry of critical rings A and D with the spatial conformation of sulfate group at C-3, keto group at C-17, and aromaticity of ring A intact. This was reflected by the antiserum, which had high specificity for E₁S, with very little or no cross-reactivity with other estrogenic as well as nonestrogenic steroids. The cross-reactivity with E₁ or estrone 3-glucuronide (<5%) does not present serious problems in our assay because the concentration of E₁S is severalfold higher than E₁ or estrone glucuronide in the serum (1).

Performance characteristics for the RIA as determined by sensitivity, intra- and interassay precision, analytical recovery, and linearity of dilution studies were acceptable. Comparison of serum samples by using the new RIA and a conventional method for measurement of E₁S showed that this new RIA does not require laborious sample pretreatment. There was excellent correlation between the two methods. However, the samples read lower with the conventional method. One possible reason could be the multiple steps involved in the conventional assay, which can result in lower recovery of E₁. Excellent correlation between the paired serum and plasma samples for E₁S values indicates that either one can be used in the assay. A positive correlation was observed between E₁ and E₁S values from the same subject, indicating the parallelism between the two estrogens in the same subject.

Earlier reports (10)(11) have indicated considerably higher serum concentrations for E₁S as compared with E₁ and E₂. In the present study, we selected several patient categories to establish the reference range for E₁S. The means, medians, and ranges for these values are presented in Fig. 5 . Normal men have a low mean value of 0.96 µg/L. Follicular phase women have the same mean value, but E₁S concentrations in luteal phase women are approximately doubled to 1.74 µg/L. In women on oral contraceptives, because the ovary is suppressed and the ethinyl estradiol, a component of birth control pills, is not recognized in this assay, the mean value is 0.74 µg/L. In postmenopausal women without HRT, the values are even lower, mean 0.13 µg/L, because the ovary is not producing appreciable amounts of estrogen (12). Conversely, when postmenopausal women are on HRT, the values are markedly increased to a mean of 2.56 µg/L, indicating that estrogen from HRT continues to be sulfated even in the absence of ovarian estrogen production. The highest values for E₁S are found in normal, singleton pregnant women; the values are even higher in late pregnancy, going from a mean of 19.5 µg/L in the first trimester to 66 µg/L and to 105 µg/L in the second and third trimesters, respectively. These values are essentially what would be expected from earlier reports and represent marked increases above the normal circulating concentrations of E₁ and E₂ (10)(11).

Monitoring E₁S because of its higher concentration and slow metabolic rate in serum would make it a more reliable marker to determine estrogenicity in women. The availability of the new, direct RIA for measurement of E₁S provides a valuable tool to study human and also veterinary physiology of this important marker of estrogenicity. Efforts are under way to develop a simple, nonisotopic E₁S enzyme immunoassay.

	Footnotes

 
¹ Nonstandard abbreviations: E₁S, estrone sulfate; E₁, estrone; E₂, estradiol; BSA, bovine serum albumin; CMO, (O-carboxymethyl)-oxime; and HRT, hormone replacement therapy.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Stanczyk FS. Steroid hormones. Mishell DR Davajan V Lobo RA eds. Infertility contraception and reproductive endocrinology 3rd ed. 1991:69-70 Blackwell Scientific Publications, Inc. Cambridge MA. .
2. Levant SG, Barnes RB. Pharmacology of estrogen. Lobo RA eds. Treatment of the postmenopausal woman 1993:57-58 Raven Press New York. .
3. Cassidenti DL, Vijod AF, Vijod MA, Stanczyk FZ, Lobo RA. Short term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1990;163:1953-1960. [ISI][Medline] [Order article via Infotrieve]
4. Hyland JH, Langsfor DA. Changes in urinary and plasma estrone sulfate concentrations after induction of fetal death in mares at 45 days of gestation. Aust Vet J 1990;67:349-351. [Medline] [Order article via Infotrieve]
5. Wright K, Collins DC, Musey PI, Preedy JRK. A specific RIA for estrone sulfate in plasma and urine without hydrolysis. J Clin Endocrinol Metab 1978;47:1092-1098. [Abstract]
6. Cox RI, Hoskinson RM, Wong MSF. Antisera reactive directly to estrone sulfate. Steroids 1979;33:549-562. [Medline] [Order article via Infotrieve]
7. Bain JD, Lasley BL. Free radical based biochemical method for detecting substances in fluids. US Patent No. 4,652,532, 1987..
8. Seevers RH, Counsell RE. Radioiodination techniques for small organic molecules. Chem Rev 1982;82:575-590.
9. Rao PN, Moore PH, Jr. Synthesis of new steroid haptens for radioimmunoassay. Steroids 1976;28:101-109. [Medline] [Order article via Infotrieve]
10. Loriaux DL, Ruder HJ, Knab DR, Lipsett MB. Estrone sulfate, estrone, estradiol and estriol plasma levels in human pregnancy. J Clin Endocrinol Metab 1972;35:887-891. [ISI][Medline] [Order article via Infotrieve]
11. Ruder HJ, Loriaux DL, Lipsett MB. Estrone sulfate production rate and metabolism in man. J Clin Invest 1972;51:1020-1033.
12. Roberts KD, Rochefort JG, Bleau G, Chapdelaine A. Plasma estrone sulfate levels in post-menopausal women. Steroids 1980;35:179-187. [Medline] [Order article via Infotrieve]